ClinicalTrialsFinder
RecruitingNCT07417605

Diagnostic Performance Of 4D Dynamic LAFOV FDG-PET Acquisition for Differentiation of Residual Disease and Post-radiation Inflammation in Head Neck SCC Treated by Radiotherapy.

Sponsor

University Hospital, Brest

Enrollment

180 participants

Start Date

Apr 13, 2026

Study Type

OBSERVATIONAL

Conditions

Head & Neck Squamous Cell Carcinoma

Summary

This multicenter prospective observational study will evaluate the value of dynamic FDG-PET LAFOV imaging during the initial therapeutic assessment of a head and neck cancer 3 months after completion of curative radiotherapy.

Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Adult patient ≥ 18 years of age
  • Presenting with head and neck squamous cell carcinoma
  • Completed curative treatment with external radiation therapy
  • Eligible for dynamic LAFOV FDG-PET scan for therapeutic evaluation at 3 months
  • Having given consent for the end-of-treatment consultation

Exclusion Criteria6

  • Hypersensitivity to 18F-FDG or other excipients contained in the contrast agent
  • Pregnancy or breastfeeding
  • History of treated upper gastrointestinal tract cancer
  • Other histology
  • Incomplete RTE treatment regimen
  • Refusal to participate

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

CHU Brest

Brest, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07417605

Related Trials

Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma

NCT074450481 location

A Study of Adaptive Radiotherapy of Head-neck Cancer Using Daily Replanning and Optimization of the Treatment Plan.

NCT075069021 location

Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)

NCT074852961 location

Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT

NCT074487271 location

Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

NCT073332741 location